Research programme: antiviral therapeutics - TSRL
Latest Information Update: 26 Jun 2014
At a glance
- Originator TSRL
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Adenovirus infections; Viral infections
Most Recent Events
- 24 Jun 2014 Preclinical trials in Adenovirus infections in USA (PO)
- 24 Jun 2014 Preclinical trials in Viral infections in USA (PO)